Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 5/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SUV39H1 | O43463 | 2/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14730811 | 0.84 | LMNA (0.45) | RAB9A | |
| SCHEMBL14730704 | 0.82 | KDR (0.43) | KDRJAK2RAB9ASMYD3FLT3 | |
| SCHEMBL14730749 | 0.82 | KDR (0.44) | KDRJAK2RAB9ASMYD3FLT3 | |
| SCHEMBL14730719 | 0.81 | KDM4E (0.44) | FLT3PARP1 | |
| SCHEMBL14730703 | 0.80 | KDR (0.44) | KDRJAK2RAB9ASMYD3FLT3 | |
| SCHEMBL14730775 | 0.78 | USP30 (0.49) | KDRPARP1 | |
| SCHEMBL14731406 | 0.78 | FLT3 (0.41) | KDRJAK2RAB9ASMYD3FLT3 | |
| SCHEMBL14730718 | 0.77 | HSD17B10 (0.51) | KDRJAK2RAB9AFLT3NPC1 | |
| SCHEMBL14730796 | 0.77 | KDR (0.46) | KDRJAK2RAB9ASMYD3FLT3 | |
| SCHEMBL14730722 | 0.77 | KDR (0.46) | KDRJAK2RAB9ASMYD3FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340539-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| WO-2013026163-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | HCCS, C1R, HAVCR2 | KDR 4426/4885JAK2 3717/4885RAB9A 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.